Initiatives aim to spur development of drugs for rare diseases

04/25/2011 | Google

Several initiatives are encouraging pharmaceutical companies to bolster development of drugs for rare and neglected medical conditions. The NIH is set to launch in the fall a scientific center to transform genetic discoveries into therapies, while the International Rare Diseases Research Consortium is aiming for at least 200 more orphan drugs by 2020. Furthermore, senators introduced a bipartisan bill that would give drugmakers an incentive to developing treatments for children with rare diseases.

View Full Article in:

Google

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX